ClinicalTrials.gg
CompletedNCT04736602Updated Aug 1, 2024Results posted

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

A Phase 3 interventional study of Triptorelin pamoate 15mg in Central Precocious Puberty, sponsored by Ipsen. Completed at 7 sites in China. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
Up to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Puberty, Precocious with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Puberty, Precocious · China.

Enrollment
12th of 13
32 · median 94
Started
2021
with 1 other
Phase 3
4 of 17
1 open now
Registered
8th of 17
by date
Lead sponsor
2 of 17
Ipsen

Among the 17 studies in Puberty, Precocious with a site in China, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 8th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

4 of the 17 studies in Puberty, Precocious with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: Up to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Puberty, Precocious with a site in China, or all of them as a file.
02

Study summary

The purpose of this research was to confirm the effectiveness and safety of the study drug, Triptorelin pamoate 15mg 3-month formulation, in a Chinese population of Central Precocious Puberty (CPP) children.

03

Conditions studied

  • Central Precocious Puberty

Browse trials for

04

Who can participate

Ages eligible
Up to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Onset of development of secondary sex characteristics before 8 and 9 years in girls and boys, respectively breast development in girls or testicular enlargement in boys according to the Tanner method: Stage II
  • Pubertal response of LH to GnRH stimulation test (stimulated peak LH ≥5 IU/L)
  • Difference between bone age (BA) (according to Greulich and Pyle method) and chronological age (CA) >1 year
  • Girls with Tanner staging ≥2 for breast development and enlarged uterine length and several follicles with diameter >4 mm in the ovary at Screening visit; boys who have testicular volume ≥4 mL at Screening visit
  • Age \< 9 years old for girls and \< 10 years old for boys at initiation of triptorelin treatment
  • Weight at least 20 kg
  • Subjects will qualify for the extension phase if they sign the corresponding specific consent form, are still benefiting from treatment at the end the primary study and have not experienced any unacceptable safety issues.

Exclusion criteria

Exclusion Criteria:

  • Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex secretion
  • Non-progressing isolated premature thelarche
  • Presence of an unstable intracranial tumour or an intracranial tumour requiring neurosurgery or cerebral irradiation. Participants with hamartomas not requiring surgery are eligible
  • Evidence of renal (creatinine >1.5 x (ULN)) or hepatic impairment ( >1.5 x ULN or (ALT)/aspartate transaminase (AST) >3 x ULN)
  • Any other condition or chronic illness or treatment possibly interfering with growth or other study endpoints (e.g. chronic steroid use except topical steroids, renal failure, diabetes, moderate to severe scoliosis)
  • Prior or current therapy with a GnRH agonist (GnRHa), medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (IGF-1)
  • Diagnosis of short stature, i.e. >2.25 standard deviation (SD) below the mean height for age
  • Major medical or psychiatric illness that could interfere with study visits
  • Known to any of the test materials or related compounds
  • Use of anticoagulants (heparin and coumarin derivatives) within the 2 weeks prior to the Screening visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Triptorelin Pamoate 15mg for injection

    Triptorelin was injected at day 1 and month 3. If participants were willing to enter the extension phase, two additional Triptorelin injections were given at month 6 and month 9.

    Drug: Triptorelin pamoate 15mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation

    The LH suppression was defined as stimulated peak LH ≤3 International Units/Liter (IU/L). The GnRH stimulation test was performed by using an intravenous (IV) injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels.

    Time frame: At Month 3

Secondary outcomes

  1. Change From Baseline in Basal LH and Follicle-Stimulating Hormone (FSH) Serum Levels

    Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the value for LH and FSH levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12

  2. Percentage of Participants With LH Suppression After GnRH Stimulation

    A synthetic GnRH (gonadorelin) was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90).

    Time frame: At Months 6 and 12

  3. Change From Baseline in Peak LH and FSH Level After GnRH Stimulation

    A synthetic GnRH was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. The FSH response to GnRH stimulation was the peak FSH level among the 4 timepoints (T0, T30, T60 and T90). The LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90). Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6 and 12

  4. Percentage of Participants With Prepubertal Levels of Sex Steroids

    Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol ≤20 picogram (pg)/milliliter (mL) in female participants and testosterone ≤0.3 nanogram (ng)/mL in male participants.

    Time frame: At Months 3, 6, 9 and 12

  5. Change From Baseline in Estradiol Levels

    Estradiol serum concentration was analyzed centrally. Change from baseline was defined as the value for estradiol levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6 ,9 and 12

  6. Change From Baseline in Testosterone Levels

    Testosterone serum concentration was analyzed centrally. Change from baseline was defined as the value for testosterone levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6 ,9 and 12

  7. Percentage of Participants With Change From Baseline in Pubertal Stage

    Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.

    Time frame: Baseline (Day 1) and at Months 6 and 12

  8. Percentage of Participants With Stabilized Pubertal Stage Compared to Baseline

    Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.

    Time frame: Baseline (Day 1) and at Months 6 and 12

  9. Change From Baseline in Auxological Parameter: Height

    Auxological parameter including height was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12

  10. Change From Baseline in Auxological Parameter: Weight

    Auxological parameter including weight was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12

  11. Change From Baseline in Auxological Parameter: Growth Velocity

    Auxological parameter including growth velocity was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12

  12. Change From Baseline in Auxological Parameter: Body Mass Index (BMI)

    Auxological parameter including BMI was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12

  13. Change From Baseline in Bone Age (BA)

    BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the value for BA at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 6 and 12

  14. Change From Baseline Difference Between BA and Chronological Age (CA)

    BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the difference between BA and CA value at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 6 and 12

  15. Change From Baseline in Uterine Length

    Uterine length was determined by type B ultrasound. Change from baseline was defined as the value of uterine length at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 6 and12

  16. Change From Baseline of Testicular Volume

    Testicular volume was determined by type B ultrasound. Change from baseline was defined as the value of testicular volume at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

    Time frame: Baseline (Day 1) and at Months 6 and 12

07

Results

Posted Aug 1, 2024

Participant flow

This prospective, Phase 3, open-label, single arm, 2-phase (main study phase and an extension phase) study was conducted in children with central precocious puberty (CPP) at 6 investigational sites in China.

Main Study Phase
Participant flow — Main Study Phase
MilestoneAll Participants
Started32
Completed30
Not completed2
Withdrew: Withdrawal by parent/guardian2
Extension Phase
Participant flow — Extension Phase
MilestoneAll Participants
Started30
Completed29
Not completed1
Withdrew: Withdrawal by parent/guardian1

Outcome measures

PrimaryPercentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation

The LH suppression was defined as stimulated peak LH ≤3 International Units/Liter (IU/L). The GnRH stimulation test was performed by using an intravenous (IV) injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels.

Time frame:
At Month 3
Reported as:
Number · percentage of participants
Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation
percentage of participantsAll Participants
Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation100 (90.8 to 100)
SecondaryChange From Baseline in Basal LH and Follicle-Stimulating Hormone (FSH) Serum Levels

Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the value for LH and FSH levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6, 9 and 12
Reported as:
Mean · IU/L
Change From Baseline in Basal LH and Follicle-Stimulating Hormone (FSH) Serum Levels
IU/LAll Participants
LH, Month 3-0.6906 ± 1.6417
LH, Month 6-0.7411 ± 1.6606
LH, Month 9-0.7415 ± 1.6817
LH, Month 12-0.9310 ± 1.6367
FSH, Month 3-2.3531 ± 1.8079
FSH, Month 6-2.2307 ± 1.7445
FSH, Month 9-2.0740 ± 1.7979
FSH, Month 12-1.9413 ± 1.6996
SecondaryPercentage of Participants With LH Suppression After GnRH Stimulation

A synthetic GnRH (gonadorelin) was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90).

Time frame:
At Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With LH Suppression After GnRH Stimulation
percentage of participantsAll Participants
Month 693.5 (81.1 to 98.8)
Month 1293.5 (81.1 to 98.8)
SecondaryChange From Baseline in Peak LH and FSH Level After GnRH Stimulation

A synthetic GnRH was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. The FSH response to GnRH stimulation was the peak FSH level among the 4 timepoints (T0, T30, T60 and T90). The LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90). Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6 and 12
Reported as:
Mean · IU/L
Change From Baseline in Peak LH and FSH Level After GnRH Stimulation
IU/LAll Participants
LH, Month 3-23.0969 ± 17.9856
LH, Month 6-24.3596 ± 17.9180
LH, Month 12-23.7221 ± 18.3669
FSH, Month 3-11.2757 ± 4.5026
FSH, Month 6-11.2536 ± 4.5267
FSH, Month 12-10.4701 ± 4.8424
SecondaryPercentage of Participants With Prepubertal Levels of Sex Steroids

Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol ≤20 picogram (pg)/milliliter (mL) in female participants and testosterone ≤0.3 nanogram (ng)/mL in male participants.

Time frame:
At Months 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Prepubertal Levels of Sex Steroids
percentage of participantsAll Participants
Month 3100 (90.8 to 100)
Month 696.8 (85.6 to 99.8)
Month 990.3 (76.8 to 97.3)
Month 1293.5 (81.1 to 98.8)
SecondaryChange From Baseline in Estradiol Levels

Estradiol serum concentration was analyzed centrally. Change from baseline was defined as the value for estradiol levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6 ,9 and 12
Reported as:
Mean · pg/mL
Change From Baseline in Estradiol Levels
pg/mLAll Participants
Month 3-8.0047 ± 15.6905
Month 6-8.3011 ± 15.9093
Month 9-7.7458 ± 15.8683
Month 12-8.6204 ± 16.1359
SecondaryChange From Baseline in Testosterone Levels

Testosterone serum concentration was analyzed centrally. Change from baseline was defined as the value for testosterone levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6 ,9 and 12
Reported as:
Mean · ng/mL
Change From Baseline in Testosterone Levels
ng/mLAll Participants
Month 3-1.3650 ± 1.1734
Month 6-1.3650 ± 1.1734
Month 9-1.3650 ± 1.1734
Month 12-1.3650 ± 1.1734
SecondaryPercentage of Participants With Change From Baseline in Pubertal Stage

Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.

Time frame:
Baseline (Day 1) and at Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Change From Baseline in Pubertal Stage
percentage of participantsAll Participants
Breast development stage for female participants, Month 6, No change35.7
Breast development stage for female participants, Month 6, Reduced57.1
Breast development stage for female participants, Month 6, Increased3.6
Breast development stage for female participants, Month 6, Missing3.6
Genital development stage for male participants, Month 6, No change33.3
Genital development stage for male participants, Month 6, Reduced66.7
Genital development stage for male participants, Month 6, Increased0
Genital development stage for male participants, Month 6, Missing0
Pubic hair development stage for female participants, Month 6, No change96.4
Pubic hair development stage for female participants, Month 6, Reduced0
Pubic hair development stage for female participants, Month 6, Increased0
Pubic hair development stage for female participants, Month 6, Missing3.6
Pubic hair development stage for male participants, Month 6, No change66.7
Pubic hair development stage for male participants, Month 6, Reduced33.3
Pubic hair development stage for male participants, Month 6, Increased0
Pubic hair development stage for male participants, Month 6, Missing0
Breast development stage for female participants, Month 12, No change39.3
Breast development stage for female participants, Month 12, Reduced50.0
Breast development stage for female participants, Month 12, Increased3.6
Breast development stage for female participants, Month 12, Missing7.1
Genital development stage for male participants, Month 12, No change0
Genital development stage for male participants, Month 12, Reduced100
Genital development stage for male participants, Month 12, Increased0
Genital development stage for male participants, Month 12, Missing0
Pubic hair development stage for female participants, Month 12, No change82.1
Pubic hair development stage for female participants, Month 12, Reduced0
Pubic hair development stage for female participants, Month 12, Increased10.7
Pubic hair development stage for female participants, Month 12, Missing7.1
Pubic hair development stage for male participants, Month 12, No change66.7
Pubic hair development stage for male participants, Month 12, Reduced33.3
Pubic hair development stage for male participants, Month 12, Increased0
Pubic hair development stage for male participants, Month 12, Missing0
SecondaryPercentage of Participants With Stabilized Pubertal Stage Compared to Baseline

Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.

Time frame:
Baseline (Day 1) and at Months 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Stabilized Pubertal Stage Compared to Baseline
percentage of participantsAll Participants
Breast development stage for girls, Month 692.9 (79.2 to 98.7)
Genital development stage for boys, Month 6100 (36.8 to 100.0)
Pubic hair development stage for girls, Month 696.4 (84.1 to 99.8)
Pubic hair development stage for boys, Month 6100 (36.8 to 100.0)
Breast development stage for girls, Month 1289.3 (74.6 to 97.0)
Genital development stage for boys, Month 12100 (36.8 to 100.0)
Pubic hair development stage for girls, Month 1282.1 (66.1 to 92.7)
Pubic hair development stage for boys, Month 12100 (36.8 to 100.0)
SecondaryChange From Baseline in Auxological Parameter: Height

Auxological parameter including height was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6, 9 and 12
Reported as:
Mean · centimeter (cm)
Change From Baseline in Auxological Parameter: Height
centimeter (cm)All Participants
Month 32.24 ± 0.62
Month 63.55 ± 0.69
Month 94.63 ± 0.81
Month 126.54 ± 0.88
SecondaryChange From Baseline in Auxological Parameter: Weight

Auxological parameter including weight was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6, 9 and 12
Reported as:
Mean · kilogram (kg)
Change From Baseline in Auxological Parameter: Weight
kilogram (kg)All Participants
Month 31.284 ± 1.319
Month 62.533 ± 1.647
Month 93.290 ± 1.899
Month 124.818 ± 2.385
SecondaryChange From Baseline in Auxological Parameter: Growth Velocity

Auxological parameter including growth velocity was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6, 9 and 12
Reported as:
Mean · cm/year
Change From Baseline in Auxological Parameter: Growth Velocity
cm/yearAll Participants
Month 3-0.895 ± 3.637
Month 6-3.769 ± 2.806
Month 9-4.804 ± 2.927
Month 12-2.052 ± 3.089
SecondaryChange From Baseline in Auxological Parameter: Body Mass Index (BMI)

Auxological parameter including BMI was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 3, 6, 9 and 12
Reported as:
Mean · kg/meter square
Change From Baseline in Auxological Parameter: Body Mass Index (BMI)
kg/meter squareAll Participants
Month 30.142 ± 0.702
Month 60.470 ± 0.791
Month 90.585 ± 0.849
Month 120.895 ± 1.081
SecondaryChange From Baseline in Bone Age (BA)

BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the value for BA at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 6 and 12
Reported as:
Mean · years
Change From Baseline in Bone Age (BA)
yearsAll Participants
Month 60.233 ± 0.307
Month 120.586 ± 0.544
SecondaryChange From Baseline Difference Between BA and Chronological Age (CA)

BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the difference between BA and CA value at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 6 and 12
Reported as:
Mean · years
Change From Baseline Difference Between BA and Chronological Age (CA)
yearsAll Participants
Month 6-0.44 ± 0.53
Month 12-0.48 ± 0.57
SecondaryChange From Baseline in Uterine Length

Uterine length was determined by type B ultrasound. Change from baseline was defined as the value of uterine length at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 6 and12
Reported as:
Mean · cm
Change From Baseline in Uterine Length
cmAll Participants
Month 6-0.4012 ± 0.4391
Month 12-0.3771 ± 0.6534
SecondaryChange From Baseline of Testicular Volume

Testicular volume was determined by type B ultrasound. Change from baseline was defined as the value of testicular volume at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.

Time frame:
Baseline (Day 1) and at Months 6 and 12
Reported as:
Mean · mL
Change From Baseline of Testicular Volume
mLAll Participants
Left, Month 6-2.4022 ± 1.7109
Right, Month 6-4.7334 ± 4.4222
Left, Month 12-2.8840 ± NA
Right, Month 12-6.7975 ± 6.3958

Adverse events

Collected over Treatment-emergent adverse events were reported from the first dose of study treatment (Day 1) up to end of extension phase, a maximum of approximately 368 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/32 (0%)2/32 (6.3%)27/32 (84.4%)
Most frequent serious events
Most frequent serious events
EventAll Participants
PneumoniaInfections and infestations2/32
Most frequent other events
Showing 10 of 47
Most frequent other events
EventAll Participants
Upper respiratory tract infectionInfections and infestations10/32
Abnormal weight gainMetabolism and nutrition disorders7/32
BronchitisInfections and infestations3/32
OverweightMetabolism and nutrition disorders3/32
Vitamin D deficiencyMetabolism and nutrition disorders3/32
CoughRespiratory, thoracic and mediastinal disorders3/32
RhinorrhoeaRespiratory, thoracic and mediastinal disorders3/32
TonsillitisInfections and infestations2/32
ObesityMetabolism and nutrition disorders2/32
Rhinitis allergicRespiratory, thoracic and mediastinal disorders2/32

Baseline characteristics

Intention-To-Treat (ITT) population consisted of all participants who received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years32
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)All Participants
Mean7.6 ± 0.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female29
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Chinese32
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino32
08

Study locations

7 sites
  • Chengdu Women's and Children's Central Hospital
    Chengdu, 610073, China
  • Jiangxi Provincial Children's Hospital
    Nanchang, 330006, China
  • Children's Hospital of Nanjing
    Nanjing, 210008, China
  • Tangshan Maternal & Child Health Hospital
    Tangshan, 063000, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, 430030, China
  • Wuxi Children's Hospital
    Wuxi, 214023, China
  • Henan Children's Hospital, Zhengzhou Children's Hospital
    Zhengzhou, 450018, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.

Access criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Feb 2022, 10 months.

Results were first posted in Aug 2024, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 3, 2021
StartActual
Mar 27, 2021
Primary completionActual
Feb 9, 2022
CompletionActual
Sep 3, 2022
Results first posted
Aug 1, 2024
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04736602
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Mar 27, 2021
Primary completion
Feb 9, 2022
Completion
Sep 3, 2022
Results posted
Aug 1, 2024
Last update
Aug 1, 2024

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion